Restless Legs Syndrome: Challenges to Treatment.

Laura M Botta P, Samantha S Anguizola E, Andrea Castro-Villacañas, Diego Garcia-Borreguero

Review Sleep medicine clinics 2021 5 citations

<\/script>\n

`; }, get iframeSnippet() { const domain = 'sleepcited.com'; const params = 'pmid\u003D33985652'; return ``; }, get activeSnippet() { return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet; }, copySnippet() { navigator.clipboard.writeText(this.activeSnippet).then(() => { this.copied = true; setTimeout(() => { this.copied = false; }, 2000); }); } }" @keydown.escape.window="open = false" @click.outside="open = false">

Embed This Widget

Style

Widget powered by . Free, no account required.

Study Design

Study Type: Review
Population: None

Intervention: Restless Legs Syndrome: Challenges to Treatment. None
Comparator: None
Primary Outcome: None
Effect Direction: Positive
Risk of Bias: Unclear

Abstract

For a long time, dopaminergic treatment (DT) was the medication for restless legs syndrome. Although DT is effective and safe over the short-term, complications develop over longer periods, including augmentation, tolerance, and impulse control disorders. Nowadays, it is recommended that first-line treatment should be alpha-2 ligands, which are more effective in the absence of previous DT. As a second-line treatment, opioids, such as oxycodone extended-release with naloxone, are approved in Europe. Brain iron should be monitored before and during treatment and corrected if necessary. Two new promising non-DTs are being developed: perampanel and dipyridamole. More research is needed.

TL;DR

First-line treatment for restless legs syndrome should be alpha-2 ligands, which are more effective in the absence of previous DT, and opioids, such as oxycodone extended-release with naloxone, are approved in Europe.

Used In Evidence Reviews

A Iron for Restless Leg Syndrome

Restless Legs Syndrome: Challenges to Treatment.

Embed This Widget

Study Design

Abstract

TL;DR

Used In Evidence Reviews

Similar Papers

Dopamine and iron in the pathophysiology of restless legs syndrome (RLS).

Restless legs syndrome and pregnancy.

Treatment of restless legs syndrome: an evidence-based review and implications for clinical practice.

Restless legs syndrome: pathophysiology, clinical presentation and management.

Altered brain iron homeostasis and dopaminergic function in Restless Legs Syndrome (Willis-Ekbom Disease).

Guidelines for the first-line treatment of restless legs syndrome/Willis-Ekbom disease, prevention and treatment of dopaminergic augmentation: a combined task force of the IRLSSG, EURLSSG, and the RLS-foundation.